Compare CLMB & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | LYEL |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.6M | 320.1M |
| IPO Year | 1996 | 2021 |
| Metric | CLMB | LYEL |
|---|---|---|
| Price | $24.26 | $14.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $80.00 | $30.60 |
| AVG Volume (30 Days) | 173.4K | ★ 233.9K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $652,517,000.00 | $36,000.00 |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.83 | $8,712.13 |
| P/E Ratio | $132.56 | ★ N/A |
| Revenue Growth | ★ 40.14 | N/A |
| 52 Week Low | $15.25 | $9.03 |
| 52 Week High | $145.00 | $45.00 |
| Indicator | CLMB | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 58.33 | 50.95 |
| Support Level | $18.97 | $11.85 |
| Resistance Level | $25.12 | $19.02 |
| Average True Range (ATR) | 1.30 | 1.20 |
| MACD | 0.24 | 0.43 |
| Stochastic Oscillator | 83.27 | 87.00 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.